Results 11 to 20 of about 10,598 (216)

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects [PDF]

Diagnostics, 2021
Tropomyosin receptor kinase (TK) is encoded by the neurotrophic tyrosine receptor kinase genes (NTRK) 1, 2, and 3, whose activation plays an important role in cell cycle proliferation and survival.
Vasiliki Siozopoulou, Evelien Smits, Koen De Winne, Elly Marcq, Patrick Pauwels   +4 more
doaj   +6 more sources

Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases. [PDF]

Cancer Res Commun
The central nervous system (CNS) is a common site of metastasis for both non-small cell and small cell lung cancer, yet the therapeutic strategies to prevent and decrease lung cancer brain metastases (BM) remain limited.
Contreras-Zárate MJ, Jaramillo-Gómez JA, Marquez-Ortiz RA, Pham TC, Koliavas SN, Ormond DR, Navarro AC, Nemenoff RA, Camidge DR, Cittelly DM.   +9 more
europepmc   +3 more sources

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. [PDF]

JCO Precision Oncology, 2018
PURPOSE: Fusions that involve neurotrophic-tropomyosin receptor kinase (NTRK) genes are known drivers of oncogenesis. Therapies that target these ultra-rare, constitutionally active NTRK fusions have been remarkably effective.
Sicklick, Jason K, Bazhenova, Lyudmila, Kato, Shumei, Boichard, Amélie, Okamura, Ryosuke, Kurzrock, Razelle   +5 more
core   +6 more sources

NTRK Fusions in 1113 Solid Tumors in a Single Institution

Diagnostics, 2022
Most NTRK fusions occur at very low frequencies in various common cancers. Recent recommendations on NTRK testing recommend immunohistochemistry (IHC) as the initial test for tumor types with a low frequency of NTRK fusions.
Heejin Bang, Mi-Sook Lee, Minjung Sung, Juyoung Choi, Sungbin An, Seok-Hyung Kim, Seung Eun Lee, Yoon-La Choi   +7 more
doaj   +2 more sources

NTRK fusions are extremely rare in bone tumours [PDF]

Histopathology, 2021
Aims Because of the efficacy of tropomyosin receptor kinase (Trk) inhibitor therapy in tumours with rearrangements of the neurotrophic tyrosine kinase receptor genes (NRTK genes), there has been a surge in demand for NTRK fusion screening.
Bovee, J.V.M.G., Cleven, A.H.G., Lam, S.W., Hogendoorn, P.C.W., Bruijn, I.H.B.D., Wezel, T. van, Cleton-Jansen, A.M.   +6 more
core   +6 more sources

NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern

Human Pathology Reports, 2022
Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are oncogenic drivers found in a few rare tumours. However, NTRK rearrangements are being increasingly identified in a range of soft tissue neoplasms. Recognition of NTRK fusion-driven sarcomas is
Vanessa Young, Daniel Wong, Max Yan, Fiona Maclean   +3 more
doaj   +2 more sources

Molecular characterization of cancers with NTRK gene fusions [PDF]

Modern Pathology, 2019
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2, or NTRK3.
Swensen, Jeffrey, Vranic, Semir, Xiu, Joanne, Gatalica, Zoran   +3 more
core   +5 more sources

Molecular and clinicopathologic features of gliomas harboring NTRK fusions [PDF]

Acta Neuropathologica Communications, 2020
Fusions involving neurotrophic tyrosine receptor kinase (NTRK) genes are detected in ≤2% of gliomas and can promote gliomagenesis. The remarkable therapeutic efficacy of TRK inhibitors, which are among the first Food and Drug Administration-approved ...
Matthew Torre, Varshini Vasudevaraja, Jonathan Serrano, Michael DeLorenzo, Seth Malinowski, Anne-Florence Blandin, Melanie Pages, Azra H. Ligon, Fei Dong, David M. Meredith, MacLean P. Nasrallah, Craig Horbinski, Sonika Dahiya, Keith L. Ligon, Mariarita Santi, Shakti H. Ramkissoon, Mariella G. Filbin, Matija Snuderl, Sanda Alexandrescu   +18 more
doaj   +2 more sources

NTRK fusions in osteosarcoma are rare and non‐functional events

The Journal of Pathology: Clinical Research, 2020
Neurotrophic tyrosine receptor kinase (NTRK) fusions are promising molecular targets that have been described in a broad range of malignant tumours. Fusions commonly lead to the expression of chimeric proteins with constitutive tyrosine kinase activation
Baptiste Ameline, Karim H Saba, Michal Kovac, Linda Magnusson, Olaf Witt, Stefan Bielack, Michaela Nathrath, Karolin H Nord, Daniel Baumhoer   +8 more
doaj   +2 more sources

Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies

Blood, 2017
Chromosomal rearrangements involving the neurotrophic receptor tyrosine kinases NTRK1-3 produce oncogenic fusions in a wide variety of adult and pediatric cancers.
Pavlick, Dean, Arcila, Maria E., Mullaney, Kerry, Watts, Justin M, Hyman, David M., Diamond, Eli L, Scaltriti, Maurizio, Mughal, Tariq I, Yoshimi, Akihide, Park, Jae H., Benayed, Ryma, Tuch, Brian B., Ku, Nora, Cocco, Emiliano, Abdel-Wahab, Omar, Chung, Young Rock, Marcelus, Christina, Albacker, Lee A, Ali, Siraj M, Ebata, Kevin, Taylor, Justin, Durham, Benjamin H, Hechtman, Jaclyn F   +22 more
core   +2 more sources